Make us a preferred source
Please login to bookmark Close

US pharmaceutical giant Merck Sharp & Dohme has taken a unit of Indian generic manufacturer Lupin to court for allegedly threatening to infringe the patent for its multibillion-dollar diabetes drugs Januvia and Janumet.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
Related articles
Merck Sharp & Dohme slams Wyeth vaccine patent claims as ‘hearsay and speculation’
Intellectual Property 2019-02-06 8:17 pm By Miklos Bolza Sydney
Merck Sharp & Dohme attacks Wyeth’s ‘broad’ patent claims for Prevnar 13 vaccine
Intellectual Property 2018-12-03 8:24 pm By Miklos Bolza Sydney
Merck Sharp & Dohme loses key battle in trade mark case ahead of trial
Intellectual Property 2019-07-15 8:51 pm By Miklos Bolza Sydney
Wyeth loses privilege claim over Allens docs in Merck’s vaccine patent case
Intellectual Property 2019-10-01 3:56 pm By Miklos Bolza Sydney
Merck Sharpe & Dohme sues Lupin over Januvia patent
Healthcare 2020-09-07 2:44 pm By Cat Fredenburgh Melbourne
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au